Tolerance clinical testing of the new chemotherapeutic drug for pigs

Abstract

To study the tolerance of Ciprovet-pulmo drug for pigs 3 groups of animals were created (two experimental groups and one control ). Animals of the first experimental group were administered Ciprovet-pulmo drug at a dose of 0.045 g per 1 kg of body weight (20 mg of tiamulin and 4.5 mg of ciprofloxacin), animals of the second experimental group were injected Ciprovet-pulmo drug at a dose 5 times larger - 0.225 g per 1 kg of body weight (100 mg of tiamulin and 22.5 mg of ciprofloxacin). The piglets of the third group served as controls and were not injected. Experiments were carried out on 45 clinically healthy pigs of a large white breed at age of 2 months with an average body weight of 23.5 kg. For 10 days they were strictly monitored. A day before the drug of Ciprovet-pulmo was administered, on the fifth day and after the completion of the experiment, a clinical examination was carried out, a heart and and pulse rates were calculated, respiratory movements were counted, body temperature was meas ured. And also the blood was taken and the hematological blood parameters were studied, the physicochemical properties of urine were determined. The indicators of physiological norm for this species, breed and age of animals were used as reference. Upon completion of the test, it was found that a single oral administration of the chemotherapy Ciprovet-pulmo drug to piglets in the minimum therapeutic dose of 0.045 g per 1 kg of body weight (20 mg of tiamulin and 4.5 mg of ciprofloxacin) and in a fivefold increased dose of 0.225 g per 1 kg of body weight (100 mg of tiamulin and 22.5 mg of ciprofloxacin) does not affect the clinical and hematological parameters of animals and does not change the density and pH of urine